The combination of paclitaxel (Taxol®) and carboplatin was evaluated in a phase I/II trial in previously untreated patients with advanced ovarian cancer. Groups of patients received different doses of paclitaxel administered by 3- or 24-h infusions, as well as different doses of carboplatin, which were calculated based on area under the concentration-time curve (AUC) dosing. The combination selected for further clinical trials was paclitaxel 175 mg m-2 given in a 3-h infusion and carboplatin dosed to an AUC of 7.5, an outpatient regimen that can be administered on a 21-day cycle without immediate need for growth factor support. Carboplatin-paclitaxel has resulted in a clinical complete remission rate of 67% in 24 patients with measurable disease. Toxicity was mild, with few significant hematologic complications. On the basis of this trial, the Gynecologic Oncology Group has initiated a randomized trial in previously untreated patients with optimal stage III ovarian cancer to compare the carboplatin-paclitaxel regimen with cisplatin (75 mg m-2)-paclitaxel(135 mg m-2) by 24-h infusion.
- ovarian cancer
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.